
    
      This is a multi-center, open-label, safety extension of Aptalis (formerly Eurand) study
      PR-011 (NCT01100606) in pediatric participants with EPI due to CF. The study will be carried
      out in participants who completed the PR-011 study.

      The study is comprised of 5 visits: an enrollment visit, treatment visit 1 (3 months),
      treatment visit 2 (6 months), treatment visit 3 (9 months) and treatment visit 4 (12 months).
      Once determined eligible for participation, participants will be enrolled into the study.
    
  